SLG
AKBA icon

Stanley-Laman Group’s Akebia Therapeutics AKBA Stock Holding History

Stanley-Laman Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-316,933
Closed -$4.3M – 229
2020
Q2 		$4.3M Sell
316,933
-2,140
-0.7% -$22.1K 1.04% 32
2020
Q1 		$2.42M Buy
319,073
+6,464
+2% +$50.3K 0.73% 41
2019
Q4 		$1.98M Hold
312,609
– – 0.47% 58
2019
Q3 		$1.23M Hold
312,609
– – 0.3% 97
2019
Q2 		$1.51M Hold
312,609
– – 0.36% 78
2019
Q1 		$2.56M Sell
312,609
-21,719
-6% -$149K 0.62% 43
2018
Q4 		$1.85M Buy
334,328
+33,146
+11% +$259K 0.51% 60
2018
Q3 		$2.66M Sell
301,182
-40,307
-12% -$361K 0.65% 42
2018
Q2 		$3.41M Buy
341,489
+27,088
+9% +$271K 0.77% 36
2018
Q1 		$3M Buy
+314,401
New +$4.4M 0.68% 41

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stanley-Laman Group's AKBA Position: Q3 2020 in Review

Stanley-Laman Group sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 316,933 shares — an estimated $4.3M sold.

Stanley-Laman Group first reported a position in AKBA in Q1 2018 and held it in 10 quarters. The position peaked at $4.3M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Stanley-Laman Group reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Stanley-Laman Group sold 316,933 Akebia Therapeutics shares in Q3 2020, an estimated $4.3M.
  • Stanley-Laman Group first reported a position in Akebia Therapeutics in Q1 2018 and held it in 10 quarters.
  • Stanley-Laman Group's Akebia Therapeutics position peaked at $4.3M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Stanley-Laman Group's 13F filing for Q3 2020, filed 20 Oct 2020.